Centre National De La Recherche Scientifique

Institut Gustave Roussy

Université Paris—sud

Other

Université Paris-Sud 11

Commissariat a L'energie Atomique Et Aux Energies Alternatives

National Institute of Health and Medical Research

Institut Pasteur

National Institute for Agricultural Research

Université Paris-Saclay

Université De Versailles—saint-Quentin-En-Yvelines

University of Paris Sud XI

Centre Nationale De La Recherche Scientifique

Sanofi

Institut National De Recherche Pour L'agriculture, L'alimentation Et L'environnement

Patrick Couvreur

Didier Desmaele

Ruxandra Gref

Nicole Bru-Magniez

Thierry Martens

Michael Rivard

Pascal Breton

Angelo Paci

Christian Serre

Elias Fattal

Claude Roques-Carmes

G&eacute;rard Riess

Joachim Caron

Barbara Stella

Luigi Cattel

Gérard Ferey

Antoine Andremont

Patricia Horcajada-Cortes

Sandrine Bourgeois

Véronique Rosilio

Harivardhan Reddy Lakkireddy

Catherine Amiel

Flavio Rocco

Jack-Michel Renoir

Fran&ccedil;ois Lescure

Xavier Guillon

Thomas Berthelot

Catherine Le Visage

Francis Puisieux

Felix Augusto Rey

Stéphane Duquerroy

Bernard Sebille

Jean-François Eleouet

Fatima Zouhiri

Patricia Horcajada Cortes

Anny Slama Schwok

Bogdan Tarus

Didier Bazile

Julien Nicolas

Dominique Duchene

Elena Bellido Vera

Christina Sizun

Charles Skarbek

Nicolas Mackiewicz

Didier Desmael

Franco Dosio

Fat'ma Zouhiri

Reddy Harivardhan Lakkireddy

Anca-Lucia Laza-Knoerr

Airton Monza Da Silveira

Gilles Ponchel

Jiao Feng

Sinda Lepetre-Mouelhi

Virginie Larras

Charbel Massaad

Liliane Massade

Susan Boutary

Giorgia Maria Laura Urbinati

Didier Desmaële

The present invention relates to antisense RNAs targeting PMP22 and able to inhibit from 40% to 60% the expression of PMP22 in the cells and a pharmaceutical composition comprising thereof. The antisense RNAs are preferably siRNA and are preferably provided in the form of nanoparticles. The present invention also relates to the use of these antisense RNAs targeting PMP22 for the treatment of Charcot-Marie-Tooth 1A disease.

Antisense RNA targeting PMP22 for the treatment of Charcot-Marie-Tooth 1A disease

A bioconjugate comprising at least one neuropeptide covalently bond to at least one hydrocarbon compound of squalene structure.

Bioconjugates of neuropeptides derivatives

The invention relates to nanoparticles made from organometallic hybrid materials made from iron carboxylates, used for example as contrast agents. The particles can also be used for the encapsulation and vectoring of molecules of interest such as active pharmaceutical agents, cosmetically interesting compounds and markers. Apart from the intrinsic properties thereof for imaging, said nanoparticles give good results in terms of capacity of loading with medicaments and in biocompatibility.

Organic/inorganic hybrid nanoparticulates made from iron carboxylates

A process for preparing a porous solid with an outer surface modified by at least one polymer; the polymer being simultaneously synthetized in solution and grafted on the outer surface of the solid, includes contacting:

Porous solid with outer surface grafted with a polymer

The present invention relates to N1-benzyl substituted pyrazoles as antiviral agents directed against respiratory syncytial virus.

Antiviral agents directed against respiratory syncytial virus

The present invention relates to novel derivatives of oxazaphosphorines that are pre-activated, to the methods for preparing same, to the pharmaceutical compositions containing same and to the therapeutic use thereof, in particular for treating cancer.

Derivatives of oxazaphosphorines that are pre-activated, use and method of preparation

The present invention relates to novel derivatives of oxazaphosphorines, pharmaceutical compositions and therapeutic uses thereof, in particular for treating or preventing cancer.

Derivatives of oxazaphosphorines and therapeutic uses thereof

The invention relates to nanoparticles made from organometallic hybrid materials made from iron carboxylates, used for example as contrast agents. The particles can also be used for the encapsulation and vectoring of molecules of interest such as active3 pharmaceutical agents, cosmetically interesting compounds and markers. Apart from the intrinsic properties thereof for imaging, said nanoparticles give good results in terms of capacity for loading with medicaments and in biocompatibility.

Functional PLA-PEG copolymers, the nanoparticles thereof, their preparation and use for targeted drug delivery and imaging The present invention concerns novel functional PEG-PLA containing copolymers, the nanoparticles containing the same, their process of preparation and their use for site specific targeted drug delivery and imaging. 

Functional PLA-PEG copolymers, the nanoparticles thereof, their preparation and use for targeted drug delivery and imaging

A complex formed of at least one molecule of 5-(1,2-dihydroxy-ethyl)-3,4-dihydroxy-5H-furan-2-one or a derivative covalently bonded with at least one hydrocarbon radical with formula (A) as follows: wherein: &#x2022;-m 1=1, 2, 3, 4, 5 or 6; &#x2022;-m 2=0, 1, 2, 3, 4, 5 or 6; and represents the site of the bond with the molecule of 5-(1,2-dihydroxy-ethyl)-3,4-dihydroxy-5H-furan-2-one or derivative. Formula (I) 

Vitamin C complexes

The invention relates to a water-dispersible derivative of a therapeutic agent having a low water solubility that comprises at least one molecule of said agent covalently bonded to at least one molecule of a hydrocarbon derivative having a squalenic structure or the like. The invention further relates to corresponding nanoparticles.

Nanoparticles of therapeutic agents having low water solubility

The present invention relates to a complex made up of at least one molecule of statin or a derivative thereof, covalently bonded to at least one hydrocarbon radical including at least 18 carbon atoms and containing at least one 2-methyl-buta-2-ene unit, to nanoparticles of such a complex, and to a method for preparing same, said complex and/or said nanoparticles optionally being in the form of a lyophilizate. The present invention also relates to a pharmaceutical composition including at least one complex and/or nanoparticles such as previously defined. The invention finally relates to said complex and/or to said nanoparticles for the treatment and/or prevention of hyperlipemia and hypercholesterolemia.

Statin nanoparticles

The present invention relates to a method for preparing a cyclodextrin polymer and/or a hydrophilic polymer emulsion having cyclodextrins as well as lipophilic compounds, the emulsions having a remarkable stability. In particular, the method includes: (i) adding a lipophilic compound into an aqueous solution of a cyclodextrin unit polymer or hydrophilic polymer having cyclodextrins; (ii) forming an emulsion from the mixture resulting from step (i). The invention also relates to the resulting emulsions, i.e. stabilized emulsions by a non-covalent and non-crystalline inclusion complex consisting of (i) a cyclodextrin unit polymer or a hydrophilic polymer having cyclodextrins and (ii) a lipophilic compound. The invention also relates to the use of said emulsions in the cosmetic, pharmaceutical and/or agri-food fields.

Method for forming cyclodextrin polymer and lipophilic compound emulsions, resulting emulsions, and compositions including said emulsions

Growing community of inventors

Villebon sur Yvette, France

Patrick Couvreur